U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H30NO3
Molecular Weight 392.5115
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of TROSPIUM

SMILES

c1ccc(cc1)C(c2ccccc2)(C(=O)O[C@]3([H])C[C@]4([H])CC[C@]([H])(C3)[N+]54CCCC5)O

InChI

InChIKey=OYYDSUSKLWTMMQ-JKHIJQBDSA-N
InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23+

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB00209

Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Receptor assays showed that trospium has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses. Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder. Trospium is marketed under the brand name Sancturain the US, Tropez OD in India,Trosec in Canada, Regurin and Flotros in the United Kingdom and Spasmex in Germany, Russia, Turkey, Argentina, Chile and Israel.

CNS Activity

Curator's Comment:: Trospium chloride is hydrophilic and does not cross the normal blood-brain barrier in significant amounts and, therefore, has minimal central anticholinergic activity.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SANCTURA

Approved Use

Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. (1)

Launch Date

1.08570241E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.5 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROSPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
36.4 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROSPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.3 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROSPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
32.5%
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TROSPIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
360 mg single, oral
Highest studied dose
Dose: 360 mg
Route: oral
Route: single
Dose: 360 mg
Sources:
healthy
n = 8
Health Status: healthy
Sex: M
Population Size: 8
Sources:
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p.3
unhealthy
n = 591
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 591
Sources: Page: p.3
Disc. AE: Dry mouth...
AEs leading to
discontinuation/dose reduction:
Dry mouth (1.9%)
Sources: Page: p.3
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Disc. AE: Face angioedema, Lip angioedema...
AEs leading to
discontinuation/dose reduction:
Face angioedema
Lip angioedema
Oedema tongue
Angioedema of larynx
Somnolence
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Dry mouth 1.9%
Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p.3
unhealthy
n = 591
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 591
Sources: Page: p.3
Angioedema of larynx Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Face angioedema Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Lip angioedema Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Oedema tongue Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Somnolence Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Trospium chloride: a quaternary amine with unique pharmacologic properties.
2003 Dec
Patents

Patents

Sample Use Guides

The recommended dose of SANCTURA (Trospium) is one 20 mg tablet twice daily. SANCTURA should be dosed with water on an empty stomach, at least one hour before a meal. For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the recommended dose is 20 mg once daily at bedtime. In geriatric patients greater than or equal to 75 years of age, dose may be titrated down to 20 mg once daily based upon tolerability.
Route of Administration: Oral
After cumulative administration of increasing concentrations of trospium (1, 3, and 5 uM), agonist-induced contractions decreased significantly in bladder strips.
Name Type Language
TROSPIUM
VANDF   WHO-DD  
Common Name English
TROSPIUM [WHO-DD]
Common Name English
TROSPIUM ION
Common Name English
TROSPIUM [VANDF]
Common Name English
TROSPIUM CATION
Common Name English
3.ALPHA.-HYDROXYSPIRO(1.ALPHA.H,5.ALPHA.H-NORTROPANE-8,1'-PYRROLIDINIUM) BENZILATE
Common Name English
SPIRO(8-AZONIABICYCLO(3.2.1)OCTANE-8,1'-PYRROLIDINIUM), 3-((HYDROXYDIPHENYLACETYL)OXY)-, (1.ALPHA.,3.BETA.,5.ALPHA.)-
Common Name English
Classification Tree Code System Code
WHO-VATC QA03DA06
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
WHO-VATC QG04BD09
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
NDF-RT N0000175700
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
NDF-RT N0000000125
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
NDF-RT N0000000125
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
WHO-ATC A03DA06
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
LIVERTOX 1009
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
WHO-ATC G04BD09
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
NDF-RT N0000000125
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
NCI_THESAURUS C29704
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C78080
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY
DRUG BANK
DB00209
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY
PUBCHEM
5284632
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY
EPA CompTox
47608-32-2
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY
RXCUI
236778
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY RxNorm
CAS
47608-32-2
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY
DRUG CENTRAL
2776
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY
FDA UNII
T4Y8ORK057
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY
IUPHAR
7480
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY
EVMPD
SUB05000MIG
Created by admin on Sat Jun 26 06:10:53 UTC 2021 , Edited by admin on Sat Jun 26 06:10:53 UTC 2021
PRIMARY